BioTechne Corp (TECH)
(Delayed Data from NSDQ)
$73.52 USD
-1.26 (-1.68%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $73.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.52 USD
-1.26 (-1.68%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $73.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
Zacks News
Vertex's (VRTX) Trikafta Gets FDA Nod for CF in Children
by Zacks Equity Research
The FDA approves Vertex's (VRTX) triple combination therapy, Trikafta, for treating cystic fibrosis in children aged between six to 11 years.
Arena's (ARNA) Etrasimod Gets FDA's Orphan Drug Tag for EoE
by Zacks Equity Research
The FDA bestows an Orphan Drug status to Arena's (ARNA) lead pipeline candidate, etrasimod, for the treatment of eosinophilic esophagitis.
Alexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids
by Zacks Equity Research
The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.
bluebird (BLUE) Resumes SCD & TDT Studies as FDA Lifts Hold
by Zacks Equity Research
The FDA lifts the clinical hold on bluebird's (BLUE) studies on LentiGlobin for sickle cell disease and betibeglogene autotemcel for transfusion-dependent thalassemia. Shares rise.
Techne (TECH) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Techne (TECH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
Techne (TECH) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 19.33% and 7.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QGEN vs. TECH: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
QGEN vs. TECH: Which Stock Is the Better Value Option?
Techne (TECH) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 19.12% and 9.11%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Techne (TECH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Techne (TECH) delivered earnings and revenue surprises of 25.44% and 9.96%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Techne (TECH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aurinia Completes Final Patient Treatment in Dry Eye Study
by Zacks Equity Research
Aurinia (AUPH) that it has completed the last patient study visit in the AUDREY study evaluating voclosporin ophthalmic solution for the potential treatment of dry eye syndrome.
Celyad-Merck Team Up to Evaluate CYAD-101 in Colorectal Cancer
by Zacks Equity Research
Celyad Oncology (CYAD) collaborates with Merck to evaluate its CAR-T candidate, CYAD-101,combined with the latter's Keytruda in microsatellite stable refractory metastatic colorectal cancer.
Alexion's Ultomiris Gets Approval in Japan for Rare Disease
by Zacks Equity Research
Alexion's (ALXN) Ultomiris gets approval in Japan for the treatment of adults and children living with atypical hemolytic uremic syndrome.
bluebird-Bristol Myers' CAR T Cell Therapy BLA Accepted by FDA
by Zacks Equity Research
The FDA accepts bluebird (BLUE) and Bristol Myers Squibb's BLA for idecabtagene vicleucel for the treatment of adult patients with multiple myeloma.
Alexion's New Formulation of Ultomiris Gets CHMP Backing
by Zacks Equity Research
Alexion (ALXN) gets a positive opinion from the CHMP recommending marketing authorization for a new 100 mg/mL intravenous advanced formulation of Ultomiris in the EU.
Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab
by Zacks Equity Research
Agenus (AGEN) initiates the rolling submission of its BLA to the FDA for balstilimab alone for the treatment of recurrent/metastatic cervical cancer.
Immunomedics Releases Trodelvy Data From Cancer Studies
by Zacks Equity Research
Immunomedics (IMMU) releases data from different cancer studies on its lead drug, Trodelvy.
ChemoCentryx's NDA for Autoimmune Disease Drug Accepted by FDA
by Zacks Equity Research
The FDA accepts ChemoCentryx's (CCXI) NDA for avacopan, for the treatment of ANCA-associated vasculitis.
Dr. Reddy's Settles Revlimid Patent Suit With Bristol Myers
by Zacks Equity Research
Dr. Reddy's (RDY) settles litigation with Bristol Myers relating to patents for Revlimid (lenalidomide) capsules.
Apellis Submits Pegcetacoplan Applications to FDA and EMA
by Zacks Equity Research
Apellis (APLS) submits an NDA to the FDA and an MAA to the European Medicines Agency for pegcetacoplan for the treatment of paroxysmal nocturnal hemoglobinuria.
Novartis' Eye Drug's Safety Label Update Approved by EMA
by Zacks Equity Research
Novartis' (NVS) eye drug Beovu's safety label update receives approval from the Committee for Medicinal Products for Human Use.
Mallinckrodt Gets CRL From FDA for Terlipressin, Shares Fall
by Zacks Equity Research
Mallinckrodt (MNK) gets a Complete Response Letter from the FDA for its NDA seeking approval for terlipressin to treat adults with hepatorenal syndrome type 1.